Company intelligence / Profile preview

SM24

Ownership: Private
Development stage: Other

Overview

SM24 is a UK-based biotechnology company developing a non-invasive wearable patch for continuous metabolic health monitoring. The device aims to provide real-time insights into users' metabolic status, supporting better lifestyle and health management. The company is led by experienced founders with backgrounds in entrepreneurship, medical technology, and biochemical sensing[1][4]. No published clinical trial results are available.

Therapeutic areas: Metabolic DisordersEndocrinologyOther
Modalities: Device (Non-invasive metabolic measurement patch)
Industry: Physiological Monitoring

Partnerships

Technology partnership with Imperial College London via Martin Boutelle

Beyond the preview

Go deeper on SM24.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SM24.

Explore the full profile